ANGO Related Analyst Ratings
-
Sidoti Upgrades AngioDynamics (ANGO) to Buy
-
Analysts Sees Synergies and Struggles in AngioDynamics' (ANGO) Latest Acquisition
-
Canaccord Genuity Maintains a 'Hold' on AngioDynamics (ANGO); Bumping Estimates After Q4 Results
-
UPDATE: Canaccord Genuity Downgrades AngioDynamics (ANGO) to Hold; Waiting For Navilyst Synergies To Kick In
-
Piper Jaffray Starts AngioDynamics (ANGO) at Neutral
-
Canaccord Genuity Maintains a 'Buy' on AngioDynamics (ANGO); Q3 Preview
-
Canaccord Genuity Maintains a 'Buy' on AngioDynamics (ANGO); Huge Deal - Like the Boldness, Don't Love the Price
-
Gabelli Upgrades AngioDynamics (ANGO) to Hold; Announces $372 Mln Acquisition of Navilyst Medical
-
Canaccord Genuity Maintains a 'Buy' on AngioDynamics (ANGO); FDA's Infinite Wisdom (or Lack Thereof) Strikes Again
-
Canaccord Genuity Reiterates a 'Buy' on AngioDynamics (ANGO); Solid F2Q Offset By Recall
-
Canaccord Genuity Maintains a 'Buy' on AngioDynamics (ANGO); FQ2/12 Preview: Be Patient
-
Highlights From Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference Part I
-
CL King Raises AngioDynamics (ANGO) to Neutral
-
CL King Downgrades AngioDynamics (ANGO) to Sell
-
Canaccord Genuity Reiterates a 'Buy' on AngioDynamics (ANGO); Good Start for New CEO
-
UPDATE - Canaccord Genuity Upgraded AngioDynamics (ANGO) to Buy; Undervalued with Positive Risk/Reward
-
Canaccord Genuity Upgrades AngioDynamics (ANGO) to Buy
-
Raymond James Cuts AngioDynamics (ANGO) to Market Perform
-
Gabelli Downgrades AngioDynamics (ANGO) to Sell; CEO Change and Weak Q4 Results
-
Wedbush Downgrades AngioDynamics (ANGO) to Underperform; CEO Out, Q4 Results Fall Short, Slashing our 2012 Outlook
-
Canaccord Genuity Maintains a 'Hold' on AngioDynamics (ANGO); Final Shoe May Have Dropped
-
Canaccord Genuity Maintains a 'Hold' on AngioDynamics (ANGO); LC Bead Exit Stymies Growth, but Still See Value
-
Canaccord Genuity Maintains a 'Hold' on AngioDynamics (ANGO); In-line Q3, Stock Becoming Attractive
-
Sidoti Resumes Coverage on AngioDynamics (ANGO) at Neutral
-
Canaccord Genuity Maintains a 'Hold' on AngioDynamics (ANGO); FDA Warns ANGO on Off-Label Promotion of NanoKinfe
-
Canaccord Genuity Maintains a 'Hold' on AngioDynamics (ANGO); Solid FQ2 Results Make Us Modestly More Positive
-
Canaccord Genuity Maintains a 'Hold' on AngioDynamics (ANGO); Pre-announces Weak FQ1
-
Blue Water Capital Starts AngioDynamics (ANGO) at Buy, $19 Price Target
-
Canaccord Genuity Maintains a 'Neutral' on AngioDynamics (ANGO); Solid FQ4, Guidance Mixed
-
Wedbush Initiates Coverage on AngioDynamics (ANGO) with a Neutral; Stock Already Appears Over-Extended
-
Raymond James Upgrades AngioDynamics (ANGO) to Outperform
-
Caris & Co Maintains an Above Average on AngioDynamics (ANGO); Raises PT
-
Matrix Lighthouse Rating Changes 1/13
-
Caris & Company Downgrades AngioDynamics (ANGO) to Above Average
-
Caris & Co Initiates Coverage on AngioDynamics (ANGO) with a Buy
-
Matrix USA Rating Changes 7/28
-
Matrix USA Rating Changes 3/10
-
Canaccord Adams downgrades AngioDynamics (ANGO) to Hold
-
Raymond James Downgrades AngioDynamics (ANGO) to Market Perform
-
Matrix USA Rating Changes 2/26
-
Matrix USA Rating Changes 1/08
-
Matrix USA Rating Changes 12/04
-
Matrix USA Rating Changes 11/15
-
USA Matrix Rating Changes 10/30
-
Matrix USA Rating Changes 10/10
-
Matrix USA Research Ratings Changes 10/01
-
Matrix USA Research Rating Changes: 09/26
-
Suntrust upgrades AngioDynamics (ANGO) to Buy
-
SunTrust Starts AngioDynamics (ANGO) at Neutral
-
Piper Jaffray Starts AngioDynamics (ANGO) at Market Perform
Back to ANGO Stock Lookup
